冠心病患者CD14基因多态性与超敏C反应蛋白水平的相关性研究被引量：1

Relationship between CD14 C-260T promoter polymorphism and serum C-reactive protein levels in patients with coronary heart disease

下载PDF

导出

摘要目的探讨冠状动脉粥样硬化性心脏病(简称冠心病)患者血白细胞分化抗原14(CD14)基因C(-260)T多态性与血清超敏C反应蛋白(Hs-CRP)水平的关系。方法对240例冠心病患者应用聚合酶链反应-限制性片段长度多态性(PCR-RFLP)技术检测CD14基因多态性并测定Hs-CRP水平,分析两者之间的关系。结果240例冠心病患者CD14基因C(-260)T多态性:呈TT基因型106例(44.2%)、TC基因型82例(34.1%)、CC基因型52例(21.7%)。Hs-CRP水平:TT基因型患者Hs-CRP(4.5±2.1)mg/L与TC基因型患者[(2.7±1.2)mg/L]及CC基因型患者[(2.9±1.1)mg/L]比较差异有统计学意义(t=10.10、8.85,均P<0.05):Hs-CRP>3.0mg/L的TT基因型高危患者占79.2%,与TC基因型高危患者(50.00%)及CC基因型高危患者(36.5%)比较,差异有统计学意义(χ2=17.75、28.04,均P<0.05)。结论T等位基因纯合子可能是冠心病炎症反应的独立影响因素,CD14基因变异可能与冠心病炎症反应有关。 Objective To investigate the relationship of serum levels of high sensitivity C-reactive protein （Hs-CRP） with CD14 C-260T promoter polymorphism in patients with coronary heart disease （CHD）. Methods Serum levels of Hs-CRP were determined in 240 patients with coronary heart disease. C-260T promoter polymorphism of the CD14 gene was screened by PCR-RELP assay. Results The genotype distribution of the C-260T polymorphism of the CD14 gene was as follows：TT in 106 of 240 patients （44. 2% ）, TC in 82 of 240 patients（34. 1% ） and CC in 52 of 240 patients（21.7% ）. Patients with TI＇ subtype had increased Hs-CRP levels compared with carriers of the C allele （ P〈0. 05 ） . A higher percentage of T allele homozygotes had Hs-CRP levels 〉3 mg/L （P〈0. 05 ）. Conclusion This study indicated T allele homozygotes of CD14 gene may be an inde- pendent risk factor in systemic inflammation with stable CHD.

作者熊小泉李艳黄宪章石文

机构地区广东省中医院武汉大学附属人民医院

出处《四川医学》 CAS 2009年第8期1313-1315,共3页 Sichuan Medical Journal

关键词冠心病 CD14 基因多态性 Hs.CRP coronary heart disease CD14 gene polymorphism Hs-CRP

分类号 R541.4 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献12

1Hohda S, Kimura A, Sasaoka T, et al.As sociation study of CD14 polymorphism with myocardial infarction in a Japanese population [J]. Jpn Heart J, 2003, 44(5) : 613.
2Jaros lay A, Hubacek Jan, Pit ha, et al. C(-260)T Polymorphism in the promoter of the CD14 monocyte receptor gene as a risk factor for myocardial infarction[J]. Circulation, 1999, 99(28) : 3218.
3胡蓉,程龙献,何美安,邬堂春.武汉地区人群中CD14单核细胞受体基因启动子区多态性与冠心病的关系[J].中华老年心脑血管病杂志,2006,8(3):184-186. 被引量：2
4Roberts W I, Mouhon L, Law TC, et al. Evaluation of nine automated high-sens itivity C-reactive Protein methods : implications for clinical and epidemiological applicatlons[J]. Clin Chcm, 2001,47(3) : 418.
5Haverkate F, Thompson SG, Pyke SDM, et al. Production of Creactive protein and risk of coronary events in stable and unstable angina [J]. Lancet, 1997, 349:462.
6Zee RY, Lindpaintner K, Stink B, et al. A prospective evaluation of the CD14 C (-260)T gene polymorphism and the risk of myocanlial infarction[J]. Atheroscleros is, 2001, 154:699.
7徐耕,金国栋,傅国胜,施育平,单江.冠心病患者C反应蛋白水平及其1059G/C基因多态性的研究[J].中华心血管病杂志,2003,31(4):274-277. 被引量：35
8徐耕,金国栋,傅国胜,马骥,施育平,单江.急性冠状动脉综合征患者C-反应蛋白及其1059G/C基因多态性的研究[J].中华急诊医学杂志,2003,12(4):223-226. 被引量：54
9Arroyo-Espliguem R, El-Shamouby K, Vazquez-Rey E, et al. CD14 C(-260) T promoter polymorphism and prevalence of acute coronary syndromes[J]. Int J Cardiol, 2005, 98:307.
10Koenig W, Khuseyinova N, Hoffmann MM, et al. CD14 C(-260) T polymorphism, plasma levels of the soluble endotoxin receptor CDl4, their association with chronic infections and risk of stable coronary heart disease[J]. J Am Coll Cardiol, 2002, 40:34.

二级参考文献30

1Zee R, Ridker PM. Polymorphism in the bnman C-reactive protein (CRP) gene, plasma concentrations of CRP, end the risk of future arterial thrombosis. Atherosclemsis, 2002, 162:217-219.
2Cao H, Hegele RA. Human C-reactive protein (CLIP) 1059G/C polymorphism. J Hum Genet, 2000, 55:100-101.
3Ferranti SD, Rifai N. C-reactive protein end cardiovascular disease: a review of risk prediction end intervention. Clin Chim Acta. 2002, 317 : 1-15.
4Mueller C, Buettner HJ, Hodgson JM, et al. Inflammation and longterm mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients. Circulation, 2002,105 : 1412-1415.
5Ridker PM, Rifai N, Pfeffer M.A, et al. Long-term effects of provastatin on plasma concentration of C-reactive protein. Cholesterol and Recurrent Events (CARE) Investi~tars. Circulation, 1999,100:230-235.
6Vickers MA, Green FR, Terry C, et al. Genotype at a promoter polymorphism of the intedeukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res, 2002, 53:1029-1034.
7Hoffemeister HM, Elders R, Buttcher E, et al. Comparison of Creactive protein and terminal complement complex in patients with unstable angina pectoris versus stable .angina pectoris. Am J Cardiol, 2002, 89:909-912.
8Haidari M, Javadi E, Sadeghi B, et al. Evaluation of C-reactive protein, a sensitive marker of inflammation, as a risk factor for stable coronary artery disease. Clin Biochem, 2001, 33:309-315.
9Koenig W, Sund M, Fmhlich M, et al. C-reactlve protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Detennimmts in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circuhtion, 1999,99:237-242.
10Bidker PM, Hennekens CH, Buring JE, et al. C-reactive protein, and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl. J Med, 2000, 342:836-843.